Jaguar Health Inc （JAGX）
$34.46 +1190.64% (MktCap: 11.87M)
wow.qtsky.com/stocksearch/JAGX
Lianhe Sowell International Group Ltd （LHSW）
$0.89 +105.33% (MktCap: 3.08M)
wow.qtsky.com/stocksearch/LHSW
Zeo Energy Corp （ZEO）
$0.49 +57.04% (MktCap: 30.47M)
wow.qtsky.com/stocksearch/ZEO
Greenland Mines Ltd （GRML）
$14.15 +50.21% (MktCap: 44.96M)
wow.qtsky.com/stocksearch/GRML
CaliberCos Inc （CWD）
$0.73 +40.33% (MktCap: 7.56M)
wow.qtsky.com/stocksearch/CWD
Viking Therapeutics Inc （VKTX）
$40.85 +35.67% (MktCap: 4.77B)
wow.qtsky.com/stocksearch/VKTX
IM Cannabis Corp （IMCC）
$4.14 +34.20% (MktCap: 2.56M)
wow.qtsky.com/stocksearch/IMCC
Quanome Technologies Inc （QNME）
$0.85 +33.04% (MktCap: 29.29M)
wow.qtsky.com/stocksearch/QNME
ZK International Group Co Ltd （ZKIN）
$1.42 +32.71% (MktCap: 103.25M)
wow.qtsky.com/stocksearch/ZKIN
Indaptus Therapeutics Inc （INDP）
$3.99 +29.13% (MktCap: 612.79M)
wow.qtsky.com/stocksearch/INDP
========================
Jaguar Health Inc (JAGX)$34.46+1190.64%
wow.qtsky.com/stocksearch/JAGX
Jaguar Health (JAGX) stock experienced a significant surge today, primarily driven by the announcement that the U.S. Food and Drug Administration (FDA) granted fee waivers for the 2027 fiscal year for two of its crofelemer-based drugs. The waivers apply to Mytesi, an FDA-approved prescription drug for HIV/AIDS-related diarrhea, and Canalevia-CA1, a conditionally approved drug for chemotherapy-induced diarrhea in dogs. This regulatory relief is a positive development, as it reduces future Prescription Drug User Fee Act (PDUFA) fees and other regulatory filing costs for the company.
The dramatic increase in share price, reported at approximately +822.85% from its previous close, is not solely attributable to the fee waivers themselves. The substantial volatility and outsized move are amplified by an extremely low share float, a consequence of a recent reverse stock split. This low float created conditions conducive to a short squeeze and momentum-driven trading, which, combined with the positive regulatory news, ignited an aggressive buying surge and exchange volatility pauses. Investors should be aware of the inherent volatility in stocks with low floats, particularly when subject to short squeeze dynamics.
========================
Lianhe Sowell International Group Ltd (LHSW)$0.89+105.33%
wow.qtsky.com/stocksearch/LHSW
Lianhe Sowell International Group Ltd. (NASDAQ: LHSW) is experiencing significant upward volatility today, primarily driven by the announcement of a strategic cooperation agreement with Kumquat Technology Co., Ltd., a subsidiary of Chery Group. This partnership, disclosed on September 22, 2026, focuses on jointly developing and promoting intelligent equipment solutions for 24 processes within the automotive aftermarket. News of this collaboration has led to LHSW shares surging over 100% today, with exceptionally high trading interest and volume, significantly outperforming its sector.
While an $11 million best-efforts follow-on public offering, priced at $1.44 per unit and including warrants, closed on September 3, 2026, which could typically introduce dilution and downward pressure, today's dramatic price movement is directly attributable to the positive strategic news. The proceeds from this earlier offering were intended for research and development, market expansion, and general corporate purposes, which could indirectly support such strategic initiatives. LHSW has a history of high volatility, with its stock price fluctuating significantly in recent weeks. However, the current surge is a direct market reaction to the strategic partnership, rather than financial reports, regulatory actions, or a short squeeze.
========================
Zeo Energy Corp (ZEO)$0.49+57.04%
wow.qtsky.com/stocksearch/ZEO
Zeo Energy Corp. (ZEO) experienced significant upward volatility today, primarily driven by the announcement of a strategic cooperation agreement with Ewyze Corp. on September 22, 2026. This partnership aims to develop integrated off-grid power and data-center infrastructure, specifically targeting the soaring demand for reliable power from artificial intelligence (AI) and cloud computing workloads. The agreement addresses a critical market need by circumventing the often lengthy (five to ten years in many U.S. regions) traditional grid interconnection timelines for new data centers.
The market reacted strongly to this news, with ZEO shares trading significantly higher and experiencing an exceptionally large trading volume. For instance, the stock was up over 42% at one point today, with trading volume reaching hundreds of millions of shares, far exceeding its 100-day average. This suggests substantial investor optimism regarding Zeo Energy's expansion into the high-growth AI infrastructure sector.
While Zeo Energy did present at The Moody Capital Disruptive Growth & Life Sciences Conference on September 10, 2026, and reported its Second Quarter 2026 financial results in August, these events are not the direct catalyst for today's dramatic price movement. The recent Q2 results indicated a year-over-year revenue decrease but sequential improvement and a narrowed net loss, which typically wouldn't cause such a sharp, immediate surge. Additionally, short interest in ZEO has recently decreased, indicating improving sentiment rather than a short squeeze as the primary driver. The new Ewyze partnership and its direct link to the booming AI sector are the core reasons for today's substantial fluctuation.
========================
Greenland Mines Ltd (GRML)$14.15+50.21%
wow.qtsky.com/stocksearch/GRML
Greenland Mines (GRML) experienced significant upward volatility today, primarily driven by major geopolitical developments and substantial project expansion news. The formal signing of a new security agreement between the U.S., Denmark, and Greenland at the UN General Assembly has critically re-rated Greenland’s strategic importance for Western critical mineral supply chains, directly benefiting companies like GRML. This agreement aims to restrict adversary nations from sensitive investments, effectively de-risking and highlighting the strategic value of GRML's rare earth projects. Concurrently, GRML announced an application for a new exploration license that would more than double its footprint in the highly prospective Sarfartoq rare earth magnet district, significantly expanding its long-term resource potential. The Sarfartoq project's Initial Assessment already outlines a robust high-case pre-tax NPV of approximately $2.05 billion and substantial neodymium-praseodymium (NdPr) oxide output capacity, further fueling investor enthusiasm. While the company did see a pre-market dip earlier due to a dilutive equity raise for project acquisition, the overwhelming positive sentiment from the security pact and exploration expansion has since propelled the stock sharply higher, underscoring its speculative nature as a pre-revenue critical minerals developer heavily reliant on future project value and strategic alignment.
========================
CaliberCos Inc (CWD)$0.73+40.33%
wow.qtsky.com/stocksearch/CWD
CaliberCos Inc. (CWD) is experiencing significant share price volatility, largely driven by ongoing regulatory concerns. On August 21, 2026, the company received a notice from Nasdaq stating non-compliance with the minimum bid price requirement, as its stock had traded below $1.00 for 33 consecutive business days. This notice, confirming the potential for delisting if compliance isn't regained by February 17, 2027, has created substantial uncertainty around the stock's future on the Nasdaq Capital Market. While this regulatory event is not "today's" news, it forms the critical backdrop for any drastic short-term movements.
The stock's inherent volatility is extreme, with typical weekly movements around 30%. For instance, on September 21, 2026, the stock gained 6.92% with an intraday fluctuation of over 10%, indicating its highly speculative nature amidst its low price point. This high volatility, coupled with a "WEAK" financial health rating and negative analyst sentiment, makes CWD highly susceptible to sharp daily swings on relatively minor trading volumes or news. While there was recent news of debt refinancing and the launch of new tokenization services, the primary driver for sustained price pressure and acute daily fluctuations remains the looming threat of Nasdaq delisting due to its sub-$1.00 share price. Short interest, while increased, with a days-to-cover ratio of 2.03, does not suggest a significant short squeeze is the direct cause of recent "drastic fluctuations".
========================
Viking Therapeutics Inc (VKTX)$40.85+35.67%
wow.qtsky.com/stocksearch/VKTX
Viking Therapeutics (VKTX) experienced a significant upward fluctuation today primarily due to the announcement of overwhelmingly positive top-line results from its maintenance study of VK2735. The company's dual GLP-1/GIP agonist for obesity demonstrated robust weight loss maintenance, with participants retaining up to 97% of their weight loss after transitioning from weekly to less frequent dosing regimens, including monthly and every-other-week injections. Crucially, the trial also reported an encouraging safety and tolerability profile during the maintenance phase, with gastrointestinal side effects comparable to placebo. This data suggests VK2735 offers a potentially differentiated profile in the highly competitive obesity drug market, particularly regarding dosing flexibility and tolerability. The news fueled strong investor confidence in Viking's potential to compete with established players like Eli Lilly and Novo Nordisk, whose stock fell as its post-Wegovy growth plan failed to fully ease competition fears, inadvertently highlighting the opportunity for challengers like Viking.
========================
IM Cannabis Corp (IMCC)$4.14+34.20%
wow.qtsky.com/stocksearch/IMCC
The significant volatility in IM Cannabis (IMCC) stock, including today's substantial upward movement, can be primarily attributed to a combination of factors stemming from its recent **30-for-1 reverse stock split (share consolidation)**, its precarious financial position, and speculative interest in the cannabis sector.
The reverse stock split, effective August 27, 2026, drastically reduced the number of outstanding shares from approximately 18.5 million to around 618,899, aiming to regain compliance with Nasdaq's minimum bid price requirement. This consolidation significantly tightened the stock's float, making it highly susceptible to amplified percentage price swings from relatively smaller trading volumes and dollar movements. This post-consolidation dynamic is a direct cause of the exaggerated daily fluctuations, including the approximate 166.67% surge on September 18, 2026, and today's roughly 30.96% increase.
Furthermore, IMCC operates within the highly speculative cannabis industry. Renewed optimism around global cannabis legalization or sector-specific news can trigger strong speculative buying, especially in thinly traded micro-cap stocks.
Underlying these sharp movements are the company's persistent fundamental weaknesses. IM Cannabis faces negative equity, thin liquidity, ongoing operating losses, negative cash flow, and has even cited "going concern risk". These financial vulnerabilities deter long-term investors but make the stock a prime target for high-risk, short-term momentum traders.
Finally, a very high short interest percentage (87.29% of outstanding shares as of August 28, 2026, shortly after the reverse split) likely contributed to short-squeeze dynamics on days of strong upward momentum, as short sellers were forced to cover positions in a suddenly much smaller float.
========================
Quanome Technologies Inc (QNME)$0.85+33.04%
wow.qtsky.com/stocksearch/QNME
Quanome Technologies Inc. (QNME) is experiencing a significant surge today, with its stock price spiking over 60% and reaching intraday highs above $1.70, driven primarily by speculative momentum and positive news related to its strategic shift towards artificial intelligence. The core catalyst appears to be "transformative AI breakthrough news" or "breakthrough AI-chip partnership news" which has fueled bullish sentiment and aggressive day trading interest. This comes after the company's recent announcement on September 21, 2026, of conditional plans to acquire 32 GPU server units for its AI computing infrastructure, further contributing to the narrative of AI expansion.
QNME's low-float nature amplifies these movements, making it highly susceptible to rapid price swings on elevated trading volume, creating a classic "low-float momentum play" that attracts active traders. Despite the company's financial overview indicating unprofitability from core operations in FY2025 and Q1 2026, and a recent shelf registration filing on September 2, 2026, highlighting significant regulatory and listing risks associated with its primary revenue source from China, these fundamental concerns are currently overshadowed by the speculative enthusiasm surrounding its AI ventures. The stock has already seen a 94.2% gain over the past month, suggesting a building momentum leading into today's volatility. While short interest is noted at 8.6% of the float, the primary drivers for today's drastic move are the reported AI breakthroughs and the inherent volatility of a low-float stock.
========================
ZK International Group Co Ltd (ZKIN)$1.42+32.71%
wow.qtsky.com/stocksearch/ZKIN
ZK International (NASDAQ: ZKIN) has recently experienced significant stock fluctuations, primarily driven by a combination of severe liquidity concerns and recent substantial corporate governance changes. A key factor is the disclosure from an August 21, 2026, SEC filing indicating the company holds $66 million in assets but a critically low $83,000 in cash. This stark imbalance highlights significant near-term liquidity challenges, raising investor fears about ZKIN's ability to meet operational expenses and short-term obligations without immediate external financing or asset sales.
Further exacerbating market uncertainty were the leadership shifts announced on September 11, 2026. The resignation of both the Chairman and Chief Financial Officer, with the CEO consolidating these crucial roles, signals potential instability within the company's executive structure and raises questions about corporate oversight and strategic direction. Such rapid executive changes often lead to investor apprehension and increased stock volatility.
Financially, ZKIN has a history of unprofitability, reporting negative earnings for fiscal year 2025 ($-4.0 million) and for the trailing twelve months ending March 31, 2026 ($-20.2 million). The company also recorded negative free cash flow of -$17.13 million over the past 12 months. Despite a high current ratio, the minimal cash position highlighted in the August filing overrides this, suggesting that the company's financial health is precarious. Short interest remains negligible at 0.04% of outstanding shares with a low days-to-cover ratio, effectively ruling out a short squeeze as the cause for recent movements. These combined fundamental weaknesses and governance concerns are the core drivers behind any recent substantial negative price movements for ZKIN.
========================
Indaptus Therapeutics Inc (INDP)$3.99+29.13%
wow.qtsky.com/stocksearch/INDP
Indaptus Therapeutics Inc. (INDP) is experiencing significant fluctuation today, marked by a notable decrease of approximately 9.58% in its stock price. This volatility, particularly the recent downward movement, can be primarily attributed to the market's re-evaluation of the company's recent capital raise. On September 10, 2026, Indaptus Therapeutics filed a Form 8K announcing a private placement in which it agreed to issue and sell over 20 million shares of common stock for approximately $24.0 million. While this private placement provides crucial capital for working capital, research and development, and a new venture into neurotechnology for sleep-related conditions, it also introduces significant share dilution.
Initially, news of capital infusion and a strategic review had spurred a substantial rally earlier in September, with the stock gaining as much as 225% this month at one point. However, the market appears to be increasingly factoring in the dilutive effect of issuing new shares, alongside the company's ongoing status as a clinical-stage biotechnology firm with negative earnings. Compounding this, Indaptus Therapeutics currently holds a "Sell" consensus rating from analysts. Short interest in INDP is relatively low, with only 0.10% of the public float shorted as of mid-August, making a short squeeze an unlikely driver for today's price action. Therefore, the current substantial fluctuation reflects a cooling of initial optimism and a more critical assessment of the private placement's long-term impact on shareholder value amidst a challenging financial landscape for the company.
========================
For daily analysis of top US stock market losers visit:
https://bigmovewhy.qtsky.com/us-stocks
--------------------------------------------------------
BigMoveWhy-BMW is powered by WOW!StockSearch
Tech Development by QTsky (Build your own tools)
https://wow.qtsky.com
